With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
13th February 2026 Uncategorised 0The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its application for approval of its flu shot mRNA-1010. Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior administration and this administration.”
More: With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
Source: fierce